Edwards Lifesciences Corp disclosed on July 27, 2026, that Chief Executive Officer Bernard J. Zovighian engaged in multiple transactions involving the company's common stock. The transactions included a disposition of shares through a trust arrangement and acquisitions of additional stock through both direct ownership and an indirect 401(k) holding. The disclosure, filed via a Form 4 statement of changes in beneficial ownership, provides transparency into executive trading activity at the medical device manufacturer.

Key Points

  • NYSE: EW
  • CEO Bernard Zovighian executed multiple stock transactions on July 27, 2026
  • Zovighian disposed of 2,920.5511 shares at $83.9342 per share through a trust arrangement
  • Following the transactions, Zovighian beneficially owned 98,845 shares directly and maintained indirect holdings through a trust and 401(k) plan

CEO Trading Activity on July 27, 2026

Edwards Lifesciences' Chief Executive Officer Bernard J. Zovighian conducted multiple equity transactions on July 27, 2026, according to the company's disclosure filing. The transactions involved Edwards Lifesciences common stock and reflected changes to Zovighian's beneficial ownership position in the medical device company. The filing documented both acquisitions and dispositions of securities, indicating active management of his shareholdings during the reporting period.

Zovighian holds both the positions of director and officer (CEO) at Edwards Lifesciences, as noted in the disclosure. The transactions were executed on a single date and resulted in modifications to his direct and indirect ownership stakes in the company. The regulatory filing provides a detailed record of these changes, which are required to be disclosed under Section 16 of the Securities Exchange Act of 1934.

Share Disposition Through Trust Structure

The most significant transaction in the filing involved a disposition of 2,920.5511 shares of Edwards Lifesciences common stock at a price of $83.9342 per share. This sale was executed through an indirect ownership structure identified as a trust arrangement. Following this transaction, Zovighian's indirect beneficial ownership through the trust totaled 8,915.6499 shares. The filing indicates this transaction occurred on July 27, 2026, and was coded as a sale in the regulatory documentation.

The use of a trust structure for the share disposition is a common arrangement among executives managing their investment portfolios. The disclosure specifies the nature of indirect beneficial ownership, allowing investors and regulators to understand the various structures through which company leadership maintains stakes in the organization. The transaction price of $83.9342 per share reflects market conditions on the execution date.

Direct Stock Acquisitions and Additional Holdings

In addition to the share disposition, the filing reflects acquisitions of Edwards Lifesciences common stock by Zovighian. The CEO acquired 319.6499 shares directly, bringing his direct beneficial ownership to 98,845 shares following the transactions. These acquisitions were coded as grant transactions with a price of $0.0000, suggesting they may have been equity compensation or similar non-purchase arrangements rather than open market acquisitions.

The filing also documents an acquisition of 319.6499 shares in indirect form through a trust arrangement, with the trust holdings increasing to 11,836.201 shares after the transaction. These acquisitions, along with the share disposition, demonstrate a multi-faceted approach to managing beneficial ownership across different ownership vehicles. The transactions collectively show changes in Zovighian's total beneficial ownership position at Edwards Lifesciences.

Retirement Plan Holdings and Total Ownership Position

Beyond direct and trust-based holdings, the disclosure indicates that Zovighian maintains beneficial ownership of Edwards Lifesciences shares through a 401(k) retirement plan. According to the filing, the CEO held 3,733.5603 shares indirectly through this retirement vehicle. This type of holding is common among company executives and reflects long-term investment in company equity through qualified retirement arrangements.

The combination of direct ownership, trust holdings, and 401(k) plan shares provides a comprehensive view of Zovighian's overall equity stake in Edwards Lifesciences. The diversification across ownership structures is typical for senior executives and reflects different purposes—some holdings may be tied to compensation arrangements, while others represent personal investment decisions. The filing itemizes each category separately to ensure transparency regarding the nature and form of beneficial ownership.

Transaction Codes and Regulatory Documentation

The filing employs standard Securities and Exchange Commission transaction codes to classify the nature of each trading activity. Transactions coded as "G" indicate grants, while the code "S" indicates a sale. These standardized codes allow regulators and investors to quickly understand the character of each transaction without requiring detailed interpretation. The filing demonstrates that Zovighian's activities included both equity compensation components (the grant transactions) and a direct sale of shares through his trust arrangement.

The regulatory framework requiring these disclosures exists to provide market transparency and prevent conflicts of interest. By filing detailed statements of changes in beneficial ownership, executives ensure that investors have timely information about trading activities by company leadership. The documentation includes specific dates, share quantities, prices, and ownership forms, creating a comprehensive audit trail of executive equity activities.

Beneficial Ownership Structure and Compliance

The disclosure filing clarifies that the reported transactions reflect changes in beneficial ownership only and do not necessarily identify all other securities of Edwards Lifesciences beneficially owned by Zovighian. This standard disclaimer indicates that the filing focuses specifically on transactions that occurred on July 27, 2026, and the resulting changes to ownership positions. Investors reviewing the filing should understand that it represents a snapshot of activity on a specific date rather than a comprehensive enumeration of all company securities held by the CEO.

Beneficial ownership, as defined in securities regulations, includes not only direct holdings but also situations where a person has the power to vote or dispose of securities, even if legal title rests elsewhere. The filing's detailed breakdown of direct ownership, trust holdings, and 401(k) arrangements demonstrates the complexity of executive shareholding patterns and the regulatory requirement to disclose these various forms of beneficial interest. The structure ensures transparency while acknowledging the different legal forms through which executives may maintain stakes in their companies.

Edwards Lifesciences and Market Context

Edwards Lifesciences Corp is a prominent player in the medical device industry, focusing on products and technologies for cardiovascular disease, structural heart disease, and critical care monitoring. As CEO, Zovighian holds significant leadership responsibility for the company's strategic direction and operational performance. Executive shareholdings, particularly those of the CEO, are closely monitored by investors as they can signal management's confidence in company prospects and alignment with shareholder interests.

The filing does not disclose forward-looking guidance, strategic plans, or management's outlook for the company. Rather, it documents specific historical transactions and resulting ownership positions. The share price of $83.9342 reflected in the sale transaction provides a data point regarding Edwards Lifesciences' valuation on July 27, 2026, though the filing does not provide context regarding broader market movements or the rationale for the transactions.

What the Disclosure Tells Investors

The Form 4 filing provides investors with transparent information about executive equity transactions, a key component of corporate governance and regulatory compliance. The transactions disclosed—including both acquisitions and a disposition—show Zovighian's active management of his ownership position in Edwards Lifesciences. Investors may use such disclosures to track whether company leadership is accumulating or reducing stakes, which some view as a signal of management's perspective on company value.

The filing represents compliance with securities regulations requiring officers and directors to disclose changes in beneficial ownership. The immediate share price impact was not clear from available public information contained in this filing. Investors interested in understanding the broader context of these transactions—such as whether they were part of regular equity compensation arrangements or represented discretionary trading decisions—may need to review additional company disclosures or investor relations materials.